Serelaxin
Serelaxin is a recombinant form of the human hormone relaxin-2. It is under development by Novartis for the treatment of acute heart failure.
Etymology[edit]
The term "Serelaxin" is derived from the hormone it is based on, "relaxin-2". The prefix "Sere-" is a common prefix used in pharmaceutical naming, often indicating a synthetic or semi-synthetic origin.
Pharmacology[edit]
Serelaxin is a vasoactive peptide hormone that mediates hemodynamic and anti-fibrotic effects with a short half-life. It is a recombinant form of the naturally occurring human relaxin-2 hormone, which is involved in the regulation of cardiovascular and renal function.
Clinical trials[edit]
Serelaxin has undergone Phase III clinical trials for the treatment of acute heart failure. The RELAX-AHF trial demonstrated that serelaxin improved symptoms and mortality in patients with acute heart failure. However, the follow-up RELAX-AHF-2 trial did not confirm these benefits.
Regulatory status[edit]
In 2013, the Food and Drug Administration (FDA) granted serelaxin Breakthrough Therapy designation for the treatment of acute heart failure. However, in 2017, the FDA declined to approve serelaxin based on the results of the RELAX-AHF-2 trial.
See also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
